Company: CYTK
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001193125-25-267059
Chunk: 10

Company: CYTOKINETICS INC
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 3
Chunk 10
---
Our exposure to market risk has not changed materially since our disclosures in "Item 7A —Quantitative and Qualitative Disclosures About Market Risk” in our Annual Report on Form 10-K for the year ended December 31, 2024, except for the following:

Interest Rate Risk 

We are exposed to market risk related to changes in interest rates. As of September 30, 2025, our cash and investments totaled $1.3 billion, comprising U.S. Treasury securities, U.S. and non-U.S. government agency bonds, commercial paper, a global portfolio of corporate debt, money market funds, and repurchase agreements backed by U.S. Treasury securities.

Our investments are subject to interest rate risk and could fall in value if market interest rates increase. We have not been exposed to, nor do we anticipate being exposed to, material risks due to changes in interest rates. A hypothetical 1% increase in market interest rates would result in a decline in the value of our investments of approximately $6.0 million and $6.1 million as of September 30, 2025 and December 31, 2024, respectively. 

In addition, we have elected the fair value option for certain liabilities. The fair value of the liabilities related to 2024 RP OM Loan Agreement, the RP Ulacamten RPA, and the derivatives of the RP Multi Tranche Loan Agreement will increase as market interest rates decrease. In addition, the fair value of the liabilities may fluctuate based upon changes in the Company’s credit rating. Changes in the interest rate environment and the credit rating of the Company could have an effect on our future earnings. For example, a hypothetical 1% decrease in the discount rates used to measure the 2024 RP OM Loan Agreement, the RP Ulacamten RPA, and the derivatives of the RP Multi Tranche Loan Agreement would result an increase in the fair value, and the recognition of a loss, of approximately $4.9 million as of September 30, 2025. During the three and nine months ended September 30, 2025, we recognized a loss on the change in the estimated fair value of liabilities of approximately $2.8 million and $13.5 million, respectively, primarily due to changes in the discount rates used to measure the 2024 RP OM Loan Agreement and the RP Ulacamten RPA. The discount rates ranged from 11% to 17% as of September 30, 2025 and 202